Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CSK | P41240 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24932950 | 0.89 | HSD17B2 (0.52) | HSD17B1HSD17B2BRD4SCN9A | |
| SCHEMBL24933349 | 0.85 | GSTP1 (0.50) | GSTP1CHEK2HSD17B1HSD17B2PARP10 | |
| SCHEMBL24933053 | 0.85 | KDM4E (0.44) | HSD17B1HSD17B2 | |
| SCHEMBL30896275 | 0.85 | LMNA (0.45) | HSD17B1HSD17B2 | |
| SCHEMBL24933007 | 0.84 | PPARD (0.44) | HSD17B1HSD17B2 | |
| SCHEMBL24933335 | 0.83 | HSD17B2 (0.44) | HSD17B1HSD17B2 | |
| SCHEMBL24933256 | 0.83 | PDK2 (0.43) | CHEK2HSD17B1HSD17B2BRD4XDH | |
| SCHEMBL24933605 | 0.82 | HSD17B2 (0.41) | HSD17B1HSD17B2XDH | |
| SCHEMBL24933312 | 0.82 | BTK (0.42) | CHEK2HSD17B1HSD17B2BTK | |
| SCHEMBL24933359 | 0.81 | HSD17B2 (0.50) | HSD17B1HSD17B2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | PNPO, PDXK, PLPBP | GSTP1 3746/4885CHEK2 985/4885HSD17B1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.